54001 Efficacy of Risankizumab for Moderate-to-Severe Plaque Psoriasis Through 304 Weeks: Subgroup Analysis by Baseline Demographics and Disease Characteristics from the LIMMitless Trial
Journal of the American Academy of Dermatology（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined